Merck receives FDA approval for type 2 diabetes therapy
JANUMET XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both sitagliptin and extended-release
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).